Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: preudhomme c. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).
Roumier C, Eclache V, Imbert M, Davi F, MacIntyre E, Garand R, Talmant P, Lepelley P, Lai JL, Casasnovas O, Maynadie M, Mugneret F, Bilhou-Naberra C, Valensi F, Radford I, Mozziconacci MJ, Arnoulet C, Duchayne E, Dastugue N, Cornillet P, Daliphard S, Garnache F, Boudjerra N, Jouault H, Fenneteau O, Pedron B, Berger R, Flandrin G, Fenaux P, Preudhomme C; Groupe Francais de Cytogenetique Hematologique (GFCH); Groupe Français d'Hématologie Cellulaire (GFHC). Roumier C, et al. Among authors: preudhomme c. Blood. 2003 Feb 15;101(4):1277-83. doi: 10.1182/blood-2002-05-1474. Epub 2002 Oct 10. Blood. 2003. PMID: 12393381 Free article.
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.
Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, de Revel T, Simon M, Dupriez B, Renoux M, Janvier M, Micléa JM, Thomas X, Bastard C, Preudhomme C, Bauters F, Degos L, Dombret H. Castaigne S, et al. Among authors: preudhomme c. Blood. 2004 Oct 15;104(8):2467-74. doi: 10.1182/blood-2003-10-3561. Epub 2004 May 13. Blood. 2004. PMID: 15142880 Free article. Clinical Trial.
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM, Terre C, Tigaud I, Castaigne S, Raffoux E, De Botton S, Fenaux P, Dombret H, Preudhomme C. Boissel N, et al. Among authors: preudhomme c. Blood. 2005 Nov 15;106(10):3618-20. doi: 10.1182/blood-2005-05-2174. Epub 2005 Jul 26. Blood. 2005. PMID: 16046528 Free article.
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D. Jovanovic JV, et al. Among authors: preudhomme c. Blood. 2007 Jun 1;109(11):4635-40. doi: 10.1182/blood-2006-10-050054. Epub 2007 Feb 13. Blood. 2007. PMID: 17299092 Free article.
394 results